Background
Methods
Results
Physicians
Patients and prescriptions
Diagnoses
Diagnosis [ICD-10] | Total [%] | Female [%] | Male [%] |
---|---|---|---|
60-74 years (n = 2127)
| |||
Hypertensive diseases [I10-I15] | 25.1 | 23.3 | 28.6 |
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, and related tissue [C00-C75] | 19.0 | 20.8 | 15.5 |
Mood [affective] disorders [F30-F39] | 11.9 | 13.0 | 7.2 |
Dorsopathies [M40-M54] | 10.7 | 10.1 | 12.0 |
Arthropathies [M00-M25] | 9.1 | 10.1 | 7.1 |
Episodic and paroxysmal disorders* [G40-G47] | 8.3 | 9.0 | 6.8 |
Other forms of heart disease [I30-I52] | 8.3 | 8.1 | 8.6 |
General symptoms and signs [R50-R69] | 8.2 | 8.5 | 7.7 |
Chronic lower respiratory diseases [J40-J47] | 8.0 | 8.1 | 7.9 |
Diabetes mellitus [E10-E14] | 6.3 | 4.4 | 10.0 |
75-79 years (n = 396)
| |||
Hypertensive diseases [I10-I15] | 33.6 | 31.9 | 36.6 |
Other forms of heart disease [I30-I52] | 16.4 | 15.0 | 19.0 |
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, and related tissue [C00-C75] | 12.6 | 8.3 | 20.4 |
Mood [affective] disorders [F30-F39] | 10.9 | 12.6 | 7.7 |
Ischaemic heart diseases [I20-I25] | 10.6 | 10.2 | 11.3 |
Diabetes mellitus [E10-E14] | 10.1 | 12.2 | 6.3 |
Dorsopathies [M40-M54] | 9.8 | 11.8 | 6.3 |
Arthropathies [M00-M25] | 9.8 | 10.6 | 8.5 |
Chronic lower respiratory diseases [J40-J47] | 9.3 | 7.5 | 12.7 |
Organic, including symptomatic, mental disorders** [F00-F09] | 6.8 | 6.7 | 7.0 |
80 years or older (n = 553)
| |||
Hypertensive diseases [I10-I15] | 39.4 | 39.6 | 38.8 |
Other forms of heart disease [I30-I52] | 32.9 | 33.3 | 22.3 |
Ischaemic heart diseases [I20-I25] | 16.8 | 16.7 | 17.4 |
Arthropathies [M00-M25] | 15.7 | 17.6 | 9.1 |
Dorsopathies [M40-M54] | 12.8 | 12.3 | 14.9 |
Episodic and paroxysmal disorders* [G40-G47] | 12.3 | 13.0 | 9.9 |
Organic, including symptomatic, mental disorders** [F00-F09] | 11.6 | 11.1 | 13.2 |
Osteopathies and chondropathies [M80-M94] | 9.9 | 12.3 | 1.7 |
Chronic lower respiratory diseases [J40-J47] | 9.8 | 8.8 | 13.2 |
Mood [affective] disorders [F30-F39] | 9.4 | 9.5 | 9.1 |
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, and related tissue [C00-C75] | 9.4 | 8.6 | 12.4 |
Pharmacological therapy
Total | Only CAM treatment | CAM and conventional treatment combined | Only conventional treatment | ||||
---|---|---|---|---|---|---|---|
N | n | % | n | % | n | % | |
Total
|
12314
|
3758
|
30.5
|
1858
|
15.1
|
6698
|
54.4
|
Consultation type
| |||||||
First | 1845 | 664 | 36.0 | 139 | 7.5 | 1042 | 56.5 |
Follow-up | 10469 | 3094 | 29.6 | 1719 | 16.4 | 5656 | 54.0 |
Physician specialization
| |||||||
GP | 7956 | 2376 | 29.9 | 1161 | 14.6 | 4419 | 55.5 |
Internal medicine | 2527 | 972 | 38.5 | 427 | 16.9 | 1128 | 44.6 |
Other | 1831 | 410 | 22.4 | 270 | 14.7 | 1151 | 62.9 |
Age (y)
| |||||||
60-74 | 7320 | 2648 | 36.2 | 1134 | 15.5 | 3538 | 48.3 |
75-79 | 1762 | 409 | 23.2 | 239 | 13.6 | 1114 | 63.2 |
> 80 | 3232 | 701 | 21.7 | 485 | 15.0 | 2046 | 63.3 |
Sex
| |||||||
male | 3567 | 901 | 25.3 | 513 | 14.4 | 2153 | 60.4 |
female | 8747 | 2857 | 32.7 | 1345 | 15.4 | 4545 | 52.0 |
Diagnosis [ICD-10]
| |||||||
Diseases of the circulatory system [I00-I99] | 2835 | 563 | 19.9 | 424 | 15.0 | 1848 | 65.2 |
Neoplasms [C00-D48] | 1380 | 856 | 62.0 | 137 | 9.9 | 387 | 28.0 |
Diseases of the musculoskeletal system and connective tissue [M00-M99] | 1211 | 443 | 36.6 | 206 | 17.0 | 562 | 46.4 |
Endocrine, nutritional, and metabolic diseases [E00-E90] | 1103 | 148 | 13.4 | 141 | 12.8 | 814 | 73.8 |
Diseases of the nervous system [G00-G99] | 1058 | 189 | 17.9 | 119 | 11.2 | 750 | 70.9 |
Mental and behavioural disorders [F00-F99] | 901 | 260 | 28.9 | 126 | 14.0 | 515 | 57.2 |
Diseases of the digestive system [K00-K93] | 763 | 220 | 28.8 | 147 | 19.3 | 396 | 51.9 |
Diseases of the respiratory system [J00-J99] | 745 | 308 | 41.3 | 155 | 20.8 | 282 | 37.9 |
Symptoms, signs, and abnormal clinical and laboratory findings [R00-R99] | 695 | 215 | 30.9 | 133 | 19.1 | 347 | 49.9 |
Diseases of the genitourinary system [N00-N99] | 386 | 124 | 32.1 | 50 | 13.0 | 212 | 54.9 |
Diseases of the skin and subcutaneous tissue [L00-L99] | 376 | 136 | 36.2 | 67 | 17.8 | 173 | 46.0 |
Injury, poisoning, and certain other consequences of external causes [S00-T98] | 263 | 80 | 30.4 | 35 | 13.3 | 148 | 56.3 |
Certain infectious and parasitic diseases [A00-B99] | 260 | 71 | 27.3 | 62 | 23.8 | 127 | 48.8 |
Diseases of the eye and adnexa [H00-H59] | 103 | 50 | 48.5 | 19 | 18.4 | 34 | 33.0 |
Other n < 100 | 235 | 95 | 40.4 | 37 | 15.7 | 103 | 43.8 |
Medication [ATC classification] | Total | Gender | Age (y) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | 60-74 | 75-79 | > 80 | ||||||||
N | % | n | % | n | % | n | % | n | % | n | % | |
Total
|
16910
|
100.0
|
5661
|
100.0
|
11249
|
100.0
|
9303
|
100.0
|
2795
|
100.0
|
4812
|
100.0
|
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM [C09] | 1218 | 7.2 | 469 | 8.3 | 749 | 6.7 | 714 | 7.7 | 208 | 7.4 | 296 | 6.2 |
ANALGESICS [N02] | 945 | 5.6 | 298 | 5.3 | 647 | 5.8 | 571 | 6.1 | 78 | 2.8 | 296 | 6.2 |
PSYCHOLEPTICS [N05] | 823 | 4.9 | 281 | 5.0 | 541 | 4.8 | 400 | 4.3 | 144 | 5.2 | 279 | 5.8 |
DIURETICS [C03] | 795 | 4.7 | 266 | 4.7 | 529 | 4.7 | 301 | 3.2 | 157 | 5.6 | 337 | 7.0 |
BETA BLOCKING AGENTS [C07] | 740 | 4.4 | 275 | 4.9 | 465 | 4.1 | 453 | 4.9 | 116 | 4.2 | 171 | 3.6 |
PSYCHOANALEPTICS [N06] | 711 | 4.2 | 242 | 4.3 | 469 | 4.2 | 329 | 3.5 | 135 | 4.8 | 247 | 5.1 |
CARDIAC THERAPY [C01] | 648 | 3.8 | 205 | 3.6 | 358 | 3.2 | 215 | 2.3 | 116 | 4.1 | 317 | 6.6 |
ANTI-PARKINSON DRUGS [N04] | 643 | 3.8 | 363 | 6.4 | 280 | 2.5 | 296 | 3.2 | 153 | 5.5 | 194 | 4.0 |
ANTITHROMBOTIC AGENTS [B01] | 559 | 3.3 | 245 | 4.3 | 314 | 2.8 | 205 | 2.2 | 117 | 4.2 | 237 | 4.9 |
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS [M01] | 552 | 3.3 | 148 | 2.6 | 404 | 3.6 | 316 | 3.4 | 78 | 2.8 | 158 | 3.3 |
DRUGS FOR ACID RELATED DISORDERS [A02] | 506 | 3.0 | 150 | 2.6 | 356 | 3.2 | 300 | 3.2 | 57 | 2.0 | 149 | 3.1 |
CALCIUM CHANNEL BLOCKERS [C08] | 489 | 2.9 | 191 | 3.4 | 298 | 2.6 | 208 | 2.2 | 125 | 4.5 | 156 | 3.2 |
THYROID THERAPY [H03] | 440 | 2.6 | 63 | 1.1 | 377 | 3.4 | 319 | 3.4 | 61 | 2.2 | 60 | 1.2 |
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES [R03] | 438 | 2.6 | 171 | 3.0 | 267 | 2.4 | 226 | 2.4 | 100 | 3.6 | 112 | 2.3 |
DRUGS USED IN DIABETES [A10] | 426 | 2.5 | 167 | 3.0 | 259 | 2.3 | 274 | 2.9 | 76 | 2.7 | 76 | 1.6 |
MINERAL SUPPLEMENTS [A12] | 422 | 2.5 | 79 | 1.4 | 343 | 3.0 | 254 | 2.7 | 44 | 1.6 | 124 | 2.6 |
ANTIBIOTICS [J01] | 366 | 2.2 | 115 | 2.0 | 251 | 2.2 | 205 | 2.2 | 64 | 2.3 | 97 | 2.0 |
LIPID MODIFYING AGENTS [C10] | 333 | 2.0 | 141 | 2.5 | 192 | 1.7 | 237 | 2.5 | 54 | 1.9 | 42 | 0.9 |
Other n < 300 | 5856 | 34.6 | 1792 | 31.7 | 4150 | 36.9 | 3480 | 37.4 | 912 | 32.6 | 1464 | 30.4 |
Factor | AOR (95% CI) |
---|---|
Consultation type
| |
Follow-up | 1 |
First | 1.65 (1.52 - 1.79)* |
Physician specialization
| |
GP | 1 |
Internal medicine | 1.49 (1.40 - 1.58)* |
Other | 0.76 (0.70 - 0.84)* |
Age (y)**
| 0.97 (0.97 - 0.98)* |
Sex
| |
male | 1 |
female | 1.35 (1.27 - 1.43)* |
Diagnosis (groups)
| |
Hypertensive diseases [I10-I15] | 0.36 (0.32 - 0.39)* |
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, and related tissue [C00-C75] | 4.54 (4.12 - 4.99)* |
Malignant neoplasms of ill-defined, secondary, and unspecified sites [C76-C80] | 2.90 (2.54 - 3.30)* |
Arthropathies [M00-M25] | 1.36 (1.19 - 1.55)* |
Chronic lower respiratory diseases [J40-J47] | 0.59 (0.50 - 0.69)* |
Diabetes mellitus [E10-E14] | 0.17 (0.14 - 0.22)* |
Episodic and paroxysmal disorders [G40-G47] | 0.53 (0.45 - 0.63)* |
Ischaemic heart diseases [I20-I25] | 0.71 (0.60 - 0.83)* |
Extrapyramidal and movement disorders [G20-G26] | 0.46 (0.37 - 0.58)* |
Dorsopathies [M40-M54] | 1.34 (1.16 - 1.55)* |
Metabolic disorders [E70-E90] | 0.17 (0.13 - 0.22)* |
Disorders of thyroid gland [E00-E07] | 0.54 (0.45 - 0.64)* |
Interaction terms
| |
Hypertensive diseases [I10-I15] * age | 1.03 (1.02 - 1.04)* |
Extrapyramidal and movement disorders [G20-G26] * age | 1.04 (1.02 - 1.07)* |